SUA aprobă primul vaccin antigripal pe bază de ARNm pentru persoanele de peste 50 de ani

The FDA has approved Moderna's mRNA flu vaccine for adults aged 50 and older, showing 27% higher efficacy than standard vaccines. This new vaccine allows for quicker adaptation to circulating flu strains. Despite initial hesitations, an independent advisory committee unanimously supported its benefits. Moderna plans to make the vaccine available this fall.